To close the remaining funding gap required to launch the AXV-101 clinical trial, enabling the study to begin in early 2026.

To support clinical development of the first-in-human trial, including trial preparation and regulatory progress following clinical trial clearance.

To fund the preclinical development and regulatory preparation of AXV-101, a gene therapy for Bardet-Biedl Syndrome type 1 (BBS1), advancing the program toward its first human clinical trial.